Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03972228 · ClinicalTrials.gov registry record · Early Phase 1
Microdevice for Evaluating Drug Response in Site in Lung Lesions
A Early Phase 1 study of Lung Cancer and Lung Tumor, sponsored by Oliver Jonas.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT03972228: Completed Early Phase 1 study of Lung Cancer and Lung Tumor, sponsored by Oliver Jonas.
NCT03972228 is a Early Phase 1 study of Lung Cancer and Lung Tumor that has completed, run by Oliver Jonas. The registered enrollment target is 5 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03972228, a Early Phase 1 study of Lung Cancer and Lung Tumor, has completed, sponsored by Oliver Jonas.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a pilot study for placement of a tiny microdevice into lung tumors to more precisely predict tumor-specific drug sensitivity, and to help inform systemic therapeutic decisions. The microdevice will provide a novel technique for interrogating human lung tumor tissue in situ, and will uniquely facilitate assessment of response to multiple drugs simultaneously. This will not only increase the specificity of a particular participant's chosen systemic therapy, it will also augment the speed and efficiency with which investigators are able to make clinical decisions regarding choice of therapy.
Primary Outcome
Safety will be measured quantitatively by the number of participants with treatment-related adverse events.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Microdevice loaded with 19 chemotherapeutic agents
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2021-09-01 |
| Phase | Early Phase 1 |
What the finished NCT03972228 record still lists
NCT03972228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Microdevice loaded with 19 chemotherapeutic agents is the first listed.
NCT03972228 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03972228 about?
NCT03972228 is a clinical study titled "Microdevice for Evaluating Drug Response in Site in Lung Lesions". This is a pilot study for placement of a tiny microdevice into lung tumors to more precisely predict tumor-specific drug sensitivity, and to help inform systemic therapeutic decisions. The microdevice will provide a novel technique for interrogating human lung tumor tissue in situ, and will uniquely...
What is the current status of trial NCT03972228?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2018-10-01. Estimated completion is 2021-09-01.
What conditions does trial NCT03972228 study?
This clinical trial studies the following conditions: Lung Cancer, Lung Tumor.
What interventions are being tested in trial NCT03972228?
The interventions under investigation include: Microdevice loaded with 19 chemotherapeutic agents (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03972228?
This trial is sponsored by Oliver Jonas, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03972228 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03972228's enrollment target sits among peer trials
5 408th of 409 higher than 1 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
RECRUITING · Early Phase 1
-
Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma
RECRUITING · Early Phase 1
-
Centralized Lung Cancer EARly Detection Among Smokers (CLEAR Study)
ACTIVE NOT RECRUITING · Early Phase 1
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI